Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

NASDAQ:KYMR - US5015751044 - Common Stock

43.48 USD
0 (0%)
Last: 9/10/2025, 8:00:02 PM
43.48 USD
0 (0%)
After Hours: 9/10/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KYMR. KYMR was compared to 541 industry peers in the Biotechnology industry. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability. KYMR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KYMR had negative earnings in the past year.
In the past year KYMR has reported a negative cash flow from operations.
In the past 5 years KYMR always reported negative net income.
In the past 5 years KYMR reported 4 times negative operating cash flow.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.35%, KYMR is in the better half of the industry, outperforming 73.38% of the companies in the same industry.
KYMR has a better Return On Equity (-28.35%) than 78.74% of its industry peers.
Industry RankSector Rank
ROA -24.35%
ROE -28.35%
ROIC N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

KYMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KYMR has more shares outstanding
The number of shares outstanding for KYMR has been increased compared to 5 years ago.
Compared to 1 year ago, KYMR has an improved debt to assets ratio.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

KYMR has an Altman-Z score of 10.39. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of KYMR (10.39) is better than 86.32% of its industry peers.
KYMR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, KYMR perfoms like the industry average, outperforming 47.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.39
ROIC/WACCN/A
WACC9.62%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.32 indicates that KYMR has no problem at all paying its short term obligations.
KYMR has a Current ratio of 8.32. This is in the better half of the industry: KYMR outperforms 74.86% of its industry peers.
KYMR has a Quick Ratio of 8.32. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of KYMR (8.32) is better than 75.23% of its industry peers.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

KYMR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.66%.
Looking at the last year, KYMR shows a very negative growth in Revenue. The Revenue has decreased by -49.51% in the last year.
The Revenue has been growing by 74.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.79%
Revenue 1Y (TTM)-49.51%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-55.26%

3.2 Future

Based on estimates for the next years, KYMR will show a decrease in Earnings Per Share. The EPS will decrease by -6.66% on average per year.
KYMR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y-20.12%
EPS Next 2Y-20.02%
EPS Next 3Y-15.24%
EPS Next 5Y-6.66%
Revenue Next Year43.04%
Revenue Next 2Y4.92%
Revenue Next 3Y-0.05%
Revenue Next 5Y4.95%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

KYMR's earnings are expected to decrease with -15.24% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.02%
EPS Next 3Y-15.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KYMR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (9/10/2025, 8:00:02 PM)

After market: 43.48 0 (0%)

43.48

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners105.03%
Inst Owner Change-1.09%
Ins Owners1.4%
Ins Owner Change5.7%
Market Cap3.11B
Analysts88.46
Price Target61.37 (41.15%)
Short Float %10.99%
Short Ratio10.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.36%
Min EPS beat(2)-14.98%
Max EPS beat(2)12.26%
EPS beat(4)2
Avg EPS beat(4)-2.49%
Min EPS beat(4)-14.98%
Max EPS beat(4)12.26%
EPS beat(8)5
Avg EPS beat(8)3.14%
EPS beat(12)6
Avg EPS beat(12)1.66%
EPS beat(16)6
Avg EPS beat(16)-2.46%
Revenue beat(2)1
Avg Revenue beat(2)30.73%
Min Revenue beat(2)-51.89%
Max Revenue beat(2)113.36%
Revenue beat(4)1
Avg Revenue beat(4)-10.45%
Min Revenue beat(4)-64.6%
Max Revenue beat(4)113.36%
Revenue beat(8)3
Avg Revenue beat(8)-3.36%
Revenue beat(12)4
Avg Revenue beat(12)-9.37%
Revenue beat(16)5
Avg Revenue beat(16)-12.7%
PT rev (1m)0.18%
PT rev (3m)6.18%
EPS NQ rev (1m)11.89%
EPS NQ rev (3m)3.1%
EPS NY rev (1m)2.3%
EPS NY rev (3m)5.74%
Revenue NQ rev (1m)16.76%
Revenue NQ rev (3m)22.17%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)10.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 69.53
P/FCF N/A
P/OCF N/A
P/B 3.2
P/tB 3.2
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-4.18
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.51
OCFYN/A
SpS0.63
BVpS13.59
TBVpS13.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.35%
ROE -28.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.55%
Cap/Sales 4.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z 10.39
F-Score1
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)412.2%
Cap/Depr(5y)364.06%
Cap/Sales(3y)25.74%
Cap/Sales(5y)21.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.79%
EPS Next Y-20.12%
EPS Next 2Y-20.02%
EPS Next 3Y-15.24%
EPS Next 5Y-6.66%
Revenue 1Y (TTM)-49.51%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-55.26%
Revenue Next Year43.04%
Revenue Next 2Y4.92%
Revenue Next 3Y-0.05%
Revenue Next 5Y4.95%
EBIT growth 1Y-72.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.21%
EBIT Next 3Y-19.06%
EBIT Next 5YN/A
FCF growth 1Y-49.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.06%
OCF growth 3YN/A
OCF growth 5YN/A